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The clinician's ability to classify a pa-
tient's neurophysiological deficits into such 
categories as mild, moderate, and severe 
does not readily allow the detection of 
small but significant changes in function 
over time. Clinical neurologists, for ex-
ample, are discovering that the standard 
neurological examination is not sufficient to 
critically evaluate new drugs and surgical 
techniques that purport to improve the per-
formance of patients in the activities of daily 
life. 1 As a result, the quantitative evaluation 
of the functional capacity of patients with 
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nervous system disorders has been receiv-
ing increased attention during the past 
few years. Clinicians are attempting to aug-
ment the standard neurological examina-
tion by assembling batteries of quantitative 
tests that measure the sensory, psycho-
Special abbreviations used 
QENF: Quantitative Examination of Neu-
rological Function 
CQNE: Clinical Quantitative Neurological 
Examination 
SADLE: Simulated Activities of Daily Liv-
ing Examination 
NPE: Neuro-Psychological Examination 
motor, and cognitive performance of pa-
tients in clinical trials. 
Most test batteries in use today suffer 
serious deficiencies. The tests, their mea-
sures, and their administration lack uni-
formity. The reliability and validity of the 
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test measures are often not cvaluated. 
Control groups, when used, lack uniformi-
ty and are often poorly matched to pa-
tient groups. Methods for motivating indi-
viduals to perform in all tests to the best 
of their ability are often not reported. 
The contribution of learning improvements 
in clinical trials as a result of repeated 
testing is usually unknown. For these rea-
sons, critical evaluation and comparisons 
of the results of most of these studies are 
qualified. 
One attempt to develop an objective 
quantitative battery of tests capable of 
measuring small changes in the neurologi-
cal function of patients involved in neuro-
pharmacological trials was initiated more 
than a decade ago by Tourtellotte and his 
associates. It involved a team of neurolo-
gists, pharmacologists, biomedical engi-
neers, psychologists, biostatisticians, pro-
grammers, and paramedical personneI. The 
purpose of this report is to describe the 
long-term development, evaluation, and use 
of this large-scale test battery, called the 
Quantitative Examination of Neurological 
Function (QENF). It is our belief that 
evaluations of the QENF, summarized here-
in, represent the minimal criteria that a 
quantitative test battery should meet be-
fore being used to determine the efficacy 
of a neuropharmacological trial. 
The QENF evolved in several stages dur-
ing the past decade. Each stage was marked 
by test development, test evaluation, and 
test use in a neuropharmacological trial. 
In this report, each stage (early de-
velopment, introduction of steadiness and 
tracking tasks, and expansion of the pres-
ent QENF) is presented sequentially with 
temporal overlaps noted. 
Early development 
Tourtellotte was among the first to quan-
titate the functional capacity of patients 
by assembling a battery of sensory and 
motor performance tests, called the Clini-
cal Quantitative Neurological Examination 
(CQ NE) .15, 36. 37 The purpose of the CQ NE 
was to obtain, whenever possible, quanti-
tative measures of the neurological func-
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tions that are evaluated qualitatively in 
the standard neurological examination. 
The CQNE was specifically designed to 
quantitatively measure many of the neuro-
logical functions that comprise the complex 
symptoms of multiple sclerosis. 
In a study conducted by Ivers and Gold-
stein,12 the most frequent symptoms of 
multiple sclerosis were found to be retro-
bulbar neuritis, diplopia, paresthesia, weak-
ness or incoordination of the upper and 
lower extremities, and gait difficulty. Im-
pairment of the upper or lower extremi-
ties is often the result of disabilities such 
as contractures, weakness, excessive or 
premature fatigue, incoordination, or pares-
thesia. These disabilities may act alone or 
in combination. Prehensibility (the grasp-
ing function), representing the most im-
portant function of the upper extremities, 
requires adequate strength of the grip, 
wrist, and shoulder; stamina; speed and 
coordination of movements; and proprio-
ceptive and protective sensation. Ambula-
tion, representing the most important func-
tion of the lower extremities, requires ade-
quate strength of hip and foot, stamina, 
speed and coordination of movements, and 
proprioceptive and protective sensation. 
These functions were emphasized in the 
selection of tests and the development of the 
CQNE. The initial battery of the CQNE 
tests measured the following neurological 
functions; visual acuity; two-point discrimi-
nation of the index finger; vibration sense of 
the finger and toe; station with eyes open 
and closed; speed of movement of the 
hand and foot; coordination of the hand; 
strength of various muscle groups; and 
fatigue measures of the speed, coordina-
tion, and strength tests. 
Kuzma and associates12, 14-16, 37 designed 
aseries of experiments to examine this 
test battery statistically. Much of their 
work involved evaluating the reproduci-
bility of the test battery using normal 
young adult subjects under various testing 
conditions (different examiners, different 
times of the day, different days, and differ-
ent weeks). The results indicated good in-
ter- and intra-examiner reproducibility 
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once the examiners (two clinicians and 
two physical therapists) were carefully 
trained. These results, supported by a later 
study,8 indicate that paramedical personnel 
(in this case, physical therapists) are as ca-
pable as clinicians in administering the tests. 
The results of this evaluation of the 
test battery had important implications. 
The clinician's time with his patients is 
not significantly increased since paramedi-
cal personnel administer the tests and an-
alyze the data. Administration of tests 
by paramedical personnel ensures a more 
perfect "blinding" of a study since para-
medical personnel are less likely to de-
tect teIltale effects of a treatment than 
a clinician. 
In addition to the reproducibility studies, 
Kuzma examined learning effects and fa-
tigue effects using young normal adults 
and multiple sclerosis patients. From the 
results of the learning studies for each 
group, it was concluded that, except for 
hip strength, there were no significant im-
pravements when the tests were admin-
istered on consecutive days. From the re-
sults of the fatigue studies, it was found 
that the measures for grip strength fatigue, 
hip strength fatigue, hand speed fatigue, 
and foot speed fatigue were meaningful 
measures of fatigue effects and that the 
measures were repraducible. 
This initial test battery, with minor modi-
fication, was used in part to obtain data 
from multiple sclerosis patients for evalu-
ating two therapeutic trials36 , 37 and the 
National Cooperative Study.10, 31, 38 The re-
sults for each trial were in agreement with 
subjective methods for assessing changes 
in neurological function. The major con-
clusion of these early studies is that the 
CQNE test battery, when administered 
by trained paramedical personnel, especial-
ly registered physical therapists, provides 
a quantitative and reliable assessment of 
neurological function. 
Development of steadiness and 
tracking tasks 
During the past six years, Biomedical 
Engineers21 have developed sub-batteries 
N europharmacological trials 231 
of tests measuring steadiness and tracking 
behavior for inclusion in the CQNE. In these 
tests, the subject is required to perform 
continuous limb movements graded along 
various spatial and temporal dimensions. 
Other tests in the CQNE do not adequately 
capture many of the basic features of the 
spatial-temporal organization of movements 
characteristic of many neurological dis-
orders. The movements required in a steadi-
ness or tracking task are a compromise 
between highly restricted movements that 
make response processes difficult to study 
and totally unrestricted ones that result 
in recording and scoring difficulties. Fur-
thermore, the standard steadiness and track-
ing apparatus, described below, provides 
complete access to the stimulus and re-
sponse re cords for both on-line and off-line 
analysis and quantitative as weIl as quali-
tatitive interpretations. 
Steadiness tasks. Albers and associates1-5 
developed a sub-battery of tests for the 
CQNE to measure one component of neuro-
logical function, steadiness, or tremor. They 
demonstrated the applicability of a hu-
man operator contral system, consisting 
of a constant force tracking task using 
a force stick with a visual display and 
auditory feedback. The subject was re-
quired to maintain a constant muscle 
tension on the force stick using only the 
index finger. The studies conducted by 
Albers and his associates were fundamental 
in later developing both steadiness and 
tracking tasks for clinical use. 
Clinical steadiness tests were first de-
veloped in 1970 for use by paramedical 
personnel. 18 The clinical instrumentation 
was also used with an accelerameter to 
obtain quantitative measures of resting, 
sustention, and static intention tremor. To 
complete the sub-battery of steadiness tests, 
a hole steadiness test was modified for 
clinical use. A study involving 60 normal 
adult subjects, 10 patients with multiple 
sclerasis, and 10 patients with Parkinson's 
disease, was designed to evaluate the stead-
iness tests. The test measures were found 
to be reliable. No significant differences 
in performance were found on the tests 
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between the dominant and nondominant 
body sides. Males, however, were shown 
to be less steady than females. Steadiness 
was found to decrease significantly with 
increasing age in tests performed with 
the arm supported and to remain invariant 
with increasing age in tests performed 
with the arm unsupported. 
The clinical instrumentation was also 
used in part to evaluate the efficacy of 
amantadine (Symmetrel) in parkinsonian 
patients who were taking levodopa. Re-
suIts indicate that with amantadine ampli-
tude measures of steadiness improve from 
65% to 89% of the normal function of 
age-matched controls. 
To measure a different type of steadi-
ness, Stribley and associates34 , 3;' developed 
a test battery of postural stance using a 
force platform. Twenty normal young adult 
subjects were recruited to evaluate mea-
sures of narrow stance, wide stance, and 
one-Ieg stance with and without support. 
No significant differences wcre found be-
tween male and fern ale subjects or be-
tween dominant and non dominant si des 
in the one-Ieg stances. Significant differ-
ences were found between eyes-open and 
eyes-closed trials. As a resuIt of these 
early studies, the postural stance tasks are 
presently being modified for use with 
CQNE. 
Tracking tasks. More recently Repa and 
associates27 - 30 developed a battery of track-
ing tasks for inclusion with the CQNE. The 
battery is similar to the one described by 
Jex and Allen13; it includes step tracking, 
random tracking, and critical tracking. Ten 
normal subjects, age-matched to parkinso-
nian patients involved in a therapeutic trial, 
were used in a test-retest study (one month 
test-retest interval ) to determine reliability 
measures and learning effects. All test mea-
sures were found to be reliable. Although all 
test scores showed an improvement on the 
second examina ti on, these improvements 
were not statistically significant. This track-
ing task battery was also used as apart of 
a neuropharmacological trial to evaluate the 
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efficacy of levodopa plus amantadine. The 
test measures, all showing improvements 
favoring levodopa plus amantadine, ap-
pear to bc at least as sensitive as most 
measures in the QENF for detecting 
changes in performance. Potvin and asso-
dates"" are presently modifying this track-
ing task battery for clinical use. 
D-Amphetamine trial. The sub-batteries 
of upper extremity steadiness and track-
ing tasks were used to determine the ef-
fects of 10 mg of d-amphetamine and a 
placebo on motor performance in 6 nor-
mal subjects.4 • G Medication was adminis-
tered in a random double-blind crossover 
design on two occasions, one week apart. 
No significant differences between the ef-
fects of the medication on resting tremor, 
sustention tremor, or precision hole steadi-
ness were found. However, sevcral co m-
pensatory tracking tasks that required sus-
tained concentration and motor coordina-
tion were significantly improved with d-
amphetamine. The results suggest that thc 
tracking tasks were sufficiently sensitive 
to detect changes in performance attribut-
able to d-amphetamine that were so small 
that the subjects themselves could not tell 
whether they had received d-amphetamine 
or placebo. 
Extension of CQNE and development 
of QENF 
Expansion of the CQNE owes much to 
Fleishman and his associates,1' 8 who, from 
the 1940's onward, administered more than 
200 different tests to thousands of basic 
trainee airmen. The methodology that 
Fleishman established and the results that 
he obtained together have served as a 
guide in modifying and extending the test 
battery. 
The present test battery includes psycho-
motor tests that are intended to measure 
many of the traits found by Fleishman. 
These tests include; rotary pursuit; simple 
re action time, Purdue pegboard; large peg, 
small peg, and pencH rotation; arm sup-
ported and arm unsupported steadiness 
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using (1) a hole steadiness apparatus and 
( 2 ) a force control stick; resting, susten-
tion, and static intention tremor using an 
accelerometer; hand speed; foot speed; 
hand coordination; and foot coordination. 
Psychomotor tests represent relatively 
unpracticed tasks that attempt to mea-
sure abilities or traits that detenninc an 
individuaI's limit of performance in a skilled 
task. An individuaI's abilities are thought 
to be dependent upon long-term learning 
and genetic factors and not likely to change 
once he reaches adulthood." Abilities differ 
from skills in the sense that skills are 
highly practiced tasks. A skill is thought 
to be dependcnt upon abilities. 
The underlying assumptions relating 
skills to abilities measured by psycho-
motor tests remain unproved. However, 
if a patient involved in a clinical trial 
claims that he is now bettel' able to button 
buttons, Or to pick up coins, or to put 
on a shirt, it is important that his claim 
be verifiable in an objective manner. Con-
sequently, aseries of timed tests that simu-
late simple skills of daily living has been 
included in the test battery. The Simu-
lated Activities of Daily Living Examina-
tion (SADLE) 20 presently includes the fol-
lowing tests: putting on a shirt, managing 
visible buttons, zipping a garment, putting 
on gloves, dialing a telephone, tying a bow, 
manipulating safety pins, handwriting, pick-
ing up coins, unwrapping a Band-Aid, 
squeezing toothpaste, cutting with a knife, 
using a fork, and arising from achair. 
The SADLE makes no attempt to sepa-
rately measure any basic components or 
abilities, but focuses on simple motor skills. 
For example, one timed test, which requires 
the subject to unbutton and button a gar-
ment as rapidly as possible, reflects a 
compound measure of the subject's re-
action time, his speed and coordination in 
moving to the button, his steadiness, and 
his fine finger manipulative abilities. The 
measures from the SADLE provide little 01' 
no information as to the nature of im-
provement in a clinical trial. From the 
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results of the examination, it cannot be 
detennined if improvements are due to 
changes in strength, reaction time, coordi-
nation, mental state, sensation, or other 
basic components. Nonetheless, the SADLE 
measures specifically those functions that 
are of great importance to the patient. 
The CQNE and SADLE complement each 
other. The SADLE measures a patient's 
capability to carry out his activitics of daily 
living. If this capability is altered in a 
cIinical trial, the CQNE describes which 
basic components have caused the change. 
In additioR to new psychomotor and 
SADLE tests, a battery of tests caIIed the 
Neuro-Psychological Examination (NPE) 
has been assembled by Smith:J3 for use 
with the CQNE and SADLE. These tests 
attempt to assess specific higher and lower 
cerebral functions. They include the Pea-
body picture vocabulary test, a color nam-
ing and recognition subtest from the Eisen-
son test for aphasia, a double simultaneous 
(face-hand) simulation test, a discrimina-
tion test of right-left and body parts, the 
Raven Colored Progressive Matrices test, 
a written and oral digit substitution test, 
and selected Wechsler Adult Intelligence 
Scale subtests (digit span, digit symbol, 
similarities, picture completion, picture ar-
rangement, and object assembly). 
Since the CQNE, SADLE, and NPE a11 
purport to evaluate neurological function 
quantitatively, the term Quantitative Ex-
amination of Neurological Function 
(QENF) is used to describe the three ex-
aminations collectively. The QENF present-
ly includes tests for many of the functions 
of the intact nervous system. With the wide 
variety of tests in the QENF, it is possible 
to select certain tests for a particular neuro-
pharmacological trial while eliminating 
others that are not relevant. 
Recent evaluations of QENF 
The re cent expansion of the QENF re-
quired extensive evaluation. Aseries of 
studies was designed to examine the effects 
of motivation, short-term and long-term 
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learning, sex, and age on performance. In 
addition, reliability of the test measures, 
various types of performance measures, and 
data reduction techniques were examined. 
A review of these studies is found below. 
Motivation and short-term leaming. A 
study of the QENF was designed to: (1) in-
vestigate the success that clinicians and 
paramedical personnel achieve in uniform-
ly and adequately motivating subjects, (2) 
compare two different kinds of normal 
control groups that are often used for 
evaluating therapeutic trials, and (3) as-
sess the effects of short-term learning (one-
half hour test-retest interval) among pa-
tients and normal subjects on successive 
examinations.19, 23, 24 
Twenty normal young adult subjects, 20 
normal older adult subjects, and 20 patients 
(10 with Parkinson's disease and 10 with 
multiple sclerosis) participated in the study. 
Each subject group was divided into two 
subgroups, a control subgroup and an in-
centive subgroup. Substantial monetary in-
centives and additional verbal encourage-
ment (in addition to that ordinarily given 
by the examiner) given to the incentive 
subgroups but not to the control sub-
groups were found insufficient to differ-
entially improve the performance of the 
matched subgroups on a subset of the 
tests in the battery. There were no im-
portant differences in motivation between 
older adult normal subjects related to 
patients and young adult normal subjects 
unrelated to patients and paid to volunteer 
their services. These results indicate that 
cIinicians and paramedical personnel are 
capable of motivating subjects uniformly 
and adequately. 
Analysis of the control subgroup data 
for short-term learning effects revealed that 
young adult normal subjects showed the 
largest improvement in performance; older 
adult normal subjects showed Iess improve-
ment; and patients with Parkinson's dis-
ease and multiple sclerosis showed es-
sentially no improvement. From these re-
sults, it is doubtful that appreciable im-
provements in the performance of patients 
Clinical Pharmacology 
and Therapeutics 
in cHnical trials can be attributed to learn-
ing. 
Reliability, long-term, and short-term 
learning effects. A study25 was designed 
to evaluate the reliability of the test mea-
sures in the QENF in a manner consistent 
with the administration of the tests in 
clinical trials. A one-month test-retest in-
terval was chosen. Normal young adult 
subjects were used since large variations 
in patients' performance could justifiably 
be attributed to disease progression and 
to exacerbations. Alternatively, the large 
variation in patient performance could arti-
ficially inHate reliability coefficients. Twenty 
normal young adult subjects were evalu-
ated once in all tests of the QENF and one 
month later were contacted for re-evalua-
tion. At the completion of the second exami-
nation, the subjects repeated a subset 
of tests to evaluate differences between 
long-term (one month test-retest interval ) 
and short-term learning (one-half hour 
test-retest interval ). 
The results of the study indicate that: 
( 1) most test measures in the test battery 
are reliable, and (2) there are no im-
portant differences between short-term and 
long-term learning effects. Of 72 tests 
evaluated, the tests for fatigue, error, vi-
bration, using a fork, and zipping a gar-
ment were found to be unreliable. With 
respect to learning effects, the largest im-
provements were found for rotary pursuit 
followed by many of the tests of coordi-
nation, particularly those requiring manual 
or finger dexterity. Only slight changes 
were found for tests of vision, strength, 
and speed of hand and foot. 
When considered with previous studies, 
the present results lend support to the 
hypothesis that appreciable improvements 
in the performance of patients in neuro-
pharmacological trials cannot be attributed 
to learning effects. 
Performance measures. Potvin19 reviewed 
methods for expressing the performance 
of patients in neuropharmacological trials 
and also methods of data reduction and 
concluded that the performance of pa-
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tients should be expressed as a percentage 
of age-sex-matched normal function. In 
analyzing the results of a neuropharmaco-
logical trial, the clinician is more interested 
in knowing how close to normal the treat-
ment has brought the patient than in know-
ing that the functional level of the patient 
is double or tripIe his functional level on 
entry to the trial. It is therefore reasonable 
to express the performance of patients in all 
tasks in the QENF as a percentage of normal 
function. Many tests in the QENF show 
significant differences in performance of 
males and females 17, 19 and therefore re-
quire that performance be matched by 
sex. As discussed below, many tests in 
the QENF show significant effects of age on 
performance and therefore require that 
performance be matched by age. Once 
the performance of patients in neuro-
pharmacological trials is expressed as a 
percentage of age-sex-matched normal 
function, the data may be reduced by 
combining individual tests into meaning-
ful indices of neurological function. 26, 39, 40 
Age effects. A study26 was designed to 
examine the effects of age on performance 
in the QENF and the importance of selecting 
proper control groups for assessing clinical 
trials. Forty normal young adult subjects, 
10 patients with Parkinson's disease and 
their 10 normal spouses, and 10 patients 
with multiple sclerosis and their 10 normal 
spouses participated in this study. Each 
subject group had equal numbers of males 
and females and differences due to sex 
were taken into account prior to analysis 
for age effects. 
Significant decreases in performance with 
increasing age were found for: (1) tests 
requiring fine coordinated movements of 
the dominant hand, (2) tests of steadi-
ness performed with the arm in a sup-
ported position, and (3) tests of re action 
time, tandem gait, and sensation. Non-
significant decreases in performance with 
increasing age were found for: (1) most 
motor tests performed by the non dominant 
hand, ( 2 ) tests of steadiness performed 
with the arm in an unsupported position, 
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and ( 3 ) tests of vision, strength, and 
speed. Where there were significant dif-
ferences among the three normal subject 
groups, it was the oldest normal subject 
group that differed from the two younger 
subject groups. 
Normal young adults did not perform 
significantly better than normal subjects 
in the age range of patients with multiple 
sclerosis; but, normal young adults per-
formed significantly better than normal 
subjects in the age range of patients with 
Parkinson's disease, especially on tasks re-
quiring fine skilled movements of the 
dominant hand and coordinated activities 
of the lower extremities. These results in-
dicated that the performance of patients 
with multiple sclerosis could be cxpressed 
as a percentage of the function of either 
age-matched normal controls or normal 
young adult controls. The performance of 
patients with Parkinson's disease could be 
expressed only as a percentage of the 
function of age-matched normal controls. 
Recent neuropharmacological trials. For-
ty-two ambulatory patients with Parkinson's 
disease participated in a double-blind 
crossover trial of amantadine and place-
bO. 39 A comprehensive battery of both 
quantitative and qualitative tests was car-
ried out on each patient after he entered 
the study, after previous standard treat-
ment was discontinued or reduced to a 
minimal tolerable dose, while on placebo, 
while on amantadine, and at three-week 
intervals. Quantitative measures revealed 
significant improvement in 10 of 19 SADLE 
tests, in several tests of strcngth and sta-
tion, and in all tests of co ordination and 
gait. When the amantadine scores were 
compared to placebo scores, an average im-
provement of 29% occurred in the SADLE, 
14% in tests of coordination, 11% for 
gait, and 3% for strength. Sensation and 
neuropsychological performance were un-
affected, and side effects were minimal. 
Comparison of amantadine scores with en-
try scores (first examination ) suggested 
that amantadine may be superior to classi-
cal medications. 
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The quantitative results were in general 
agreement with qualitative assessments. 
The neurologists judged amantadine su-
perior to placebo in 74% of the patients 
and found that all relevant symptoms and 
physical signs improved. Sixty-four per 
cent of the patients on amantadine ex-
perienced subjective improvement com-
pared to 21% on placebo. Twenty-eight 
of the 42 patients with Parkinson's disease 
participating in the amantadine trial con-
tinued their participation in the therapeu-
tic trial. Each patient began levodopa 
therapy as amantadine was gradually with-
drawn and reached a stable, maximal 
tolerable dose of levodopa within 4 to 5 
months. After evaluation on levodopa alone, 
patients were randomly allocated into two 
treatment groups, using a double-blind 
crossover design to compare levodopa with 
amantadine to levodopa with placebo. 
Quantitative measures showed levodopa 
superior to amantadine in grip strength, 
foot speed, foot coordination and gait, and 
in 6 of the 19 tests in the SADLE.40 Levo-
dopa was shown to be superior to aman-
tadine in the relief of functional dis ability 
(dressing, hygiene, feeding, speech) and in 
improving neurological signs (hand tremor, 
finger coordination, and associated move-
ments ), in general agreement with quan-
titative measures. 
The combination of levodopa and aman-
tadine proved more effective than levodopa 
and placebo on the quantitative measures 
of grip strength, pencil rotation, step track-
ing, critical tracking, foot speed, foot co-
ordination, and gait in 3 of 19 tests in 
the SADLE, and in 1 NPE test. Once again, 
quantitative and qualitative assessments of 
changes in neurological function were in 
general agreement. The results of the thera-
peutic trial indicate that amantadine pro-
vides a weak synergistic effect when given 
with levodopa. 
Conclusions 
The development, evaluation, and use 
of a large-scale battery of tests called the 
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Quantitative Examination of Neurological 
Function (QENF) have been described. 
For more than a decade, this research has 
involved the joint participation of neurol-
ogists, pharmacologists, biomedical engi-
neers, psychologists,. biostatisticians, pro-
grammers, and paramedical personnel. 
The test battery has been critically eval-
uated with respect to age, sex, motivation, 
and learning effects. In addition, the re-
liability of the test measures has been as-
sessed, the consensual validity of some 
steadiness tests has been reported, the im-
portance of adequately training paramedi-
cal personnel has been determined, and 
the importance of selecting proper control 
groups for assessing clinical trials has been 
established. Quantitative and qualitative 
assessments of changes in neurological 
function obtained from several neurophar-
macological trials have been found to be 
in general agreement. 
The results of evaluations of the QENF 
to date indicate that quantitative test bat-
teries should not be used to assess a neuro-
pharmacological trial prior to extensive 
evaluation to assure a correct assessment. 
A comprehensive evaluation of a quanti-
tative test battery is required in order to 
critically compare the results with those 
of others. Evaluations of the QENF to date 
encourage its continued development and 
the eventual realization of an automated 
examination of neurological function to 
objectively assess changes in the perform-
ance of patients in neuropharmacological 
trials. 
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